IBRANCE fails to meet primary endpoint in early breast cancer trial

Pfizer said that the phase 3 PENELOPE-B clinical trial of IBRANCE (palbociclib) in early breast cancer failed to meet its primary endpoint. The collaborative late-stage ... Read More